Current Report Filing (8-k)
August 24 2020 - 07:56AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 24, 2020
Onconova Therapeutics, Inc.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-36020
|
|
22-3627252
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
375 Pheasant Run
Newtown, PA 18940
(267) 759-3680
(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant’s Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.01 per share
|
|
ONTX
|
|
The Nasdaq Stock Market LLC
|
Common Stock Warrants
|
|
ONTXW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
Item 7.01. Regulation FD Disclosure.
On August 24, 2020, Onconova Therapeutics, Inc. (“Onconova”
or the “Company”) issued a press release announcing topline results from the Company’s pivotal Phase 3 INSPIRE
trial. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information disclosed under this Item 7.01 (including Exhibit
99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On August 24, 2020, Onconova announced topline results from
its pivotal Phase 3 INSPIRE trial, which assessed the efficacy and safety of IV rigosertib in higher-risk MDS (“HR-MDS”)
patients. The trial did not meet its primary endpoint of improved survival.
The primary endpoint of the trial was overall survival, comparing
IV rigosertib plus best supportive care to physician's choice (“PC”) plus best supportive care in patients who had
progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (“HMA”) within
nine cycles over the course of one year after initiation of HMA treatment. A pre-specified analysis in the very high risk (“VHR-MDS”)
patient subgroup was also conducted.
Results of INSPIRE demonstrated that in the
intent-to-treat analysis patients randomized to IV rigosertib resulted in overall survival of 6.4 months,
versus 6.3 months for PC (p=0.33) in the overall HR-MDS population. Overall survival in the pre-specified VHR-MDS subgroup of
patients was also not significantly different between the two study arms. There was an increase in overall survival in the PC arm post-interim analysis that was unexpected. The Company is conducting additional
analyses.
Safety analysis indicates that IV rigosertib was
generally well tolerated, with reported adverse events similar to those observed in previous clinical studies with IV rigosertib
in MDS. Serious adverse events (“SAEs”) were uncommon, with a similar profile of SAEs in both study arms.
Item 9.01 Financial Statements and Exhibits.
(d)
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: August 24, 2020
|
|
Onconova Therapeutics, Inc.
|
|
|
|
|
|
By:
|
/s/ MARK GUERIN
|
|
|
|
Name: Mark Guerin
|
|
|
|
Title: Chief Financial Officer
|
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2023 to Mar 2024